This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
Facts about Suppressor of cytokine signaling 3.
Inhibits cytokine signal transduction by binding to tyrosine kinase receptors including gp130, LIF, erythropoietin, insulin, IL12, GCSF and leptin receptors. Binding to JAK2 inhibits its kinase activity.
Human | |
---|---|
Gene Name: | SOCS3 |
Uniprot: | O14543 |
Entrez: | 9021 |
Belongs to: |
---|
No superfamily |
ATOD4; CIS3; CIS3CIS-3; Cish3; cytokine-induced SH2 protein 3; Cytokine-inducible SH2 protein 3; SOCS3; SOCS-3; SOCS-3STAT-induced STAT inhibitor 3; SSI-3; SSI-3ATOD4; SSI3MGC71791; suppressor of cytokine signaling 3
Mass (kDA):
24.77 kDA
Human | |
---|---|
Location: | 17q25.3 |
Sequence: | 17; NC_000017.11 (78356777..78360079, complement) |
Widely expressed with high expression in heart, placenta, skeletal muscle, peripheral blood leukocytes, fetal and adult lung, and fetal liver and kidney. Lower levels in thymus.
The SOCS3 protein is a possible candidate for a novel anti-cancer antibody. It has been identified as an innovative antigen by a group of scientists from Boster Bio. It is used in a variety of ways by researchers. It is a great tool for drug development especially in the field of cancer research. However, it must be noted that its use in cancer research is very limited, primarily because the SOCS3 protein is only recently discovered.
A high-performance ELISA made with Boster Bio's latest SOCS3 marker has been developed to detect a broad range of cytokines. This marker, found on monocytes, regulates the polarization of macrophages via controlling their M1 phenotype. This ELISA allows researchers to determine whether an inflammation response has been provoked or suppressed by a specific substance, like a bacterium.
SOCS3 is a key player in the development of T cells. SOCS3 stimulates T cell growth in the early stages of Thymocyte Division. A subset of T cells have a TCR composed of two chains (gd+ and ab+) and requires less processing of antigen.
The SOCS3 siRNA is a collection of three siRNAs that target specific targets. The SOCS3 siRNA was used to control the reaction. The so-called negative control was 3.3 nmol siRNA dissolved in 330mL of RNase-free distilled water. Six-well plates were used for the cultivation of BV-2 cells using Lipofectamine 2000. To transfect cells, the resulting cell culture medium was replaced with 10 percent FBS.
An ELISA built on SOCS3 can detect a broad variety of inflammation reactions. It is highly sensitive and precise. It is flexible and simple to use. The SOCS3 marker is available in several commercial formats. The widespread use of SOCS3 in a variety applications has made it more well-known in the clinical setting. The SOCS3 protein is extensively expressed in non-hematopoietic cells and is a major regulator of IL-6 levels within the immune system.
It has been shown that Th27 cells are influenced by suppressors of cytokine signals 3. SOCS3-deficient macrophages from M1 increased the expression of transcription factors specific to Th27 and increased the ability to enhance differentiation of CD4+ T cells. An ELISA basing on SOCS3 expression in T cells is a powerful instrument for diagnosing inflammation.
The suppressor of the cytokine signaling (SOCS) family of proteins block signal transduction via the JAK/STAT pathway. They are involved in regulation of IL-6-mediated signaling and are rapidly stimulated by a variety. SOCS3 is also linked to obesity and is involved in inflammation and wound healing regulation. However, its exact function is still unclear. This article provides a brief overview of its uses in hematology and in immunohistochemistry.
SOCS3 expression can cause a decrease in the survival and homeostasis of CD8ab T cell cells. SOCS3 is expressed only on Th2 cells, and not on Th2. This suggests that it may regulate T cell immunity. However, the exact molecular mechanism remains completely understood. SOCS3 is the most reliable test for understanding T cell immunity. While SOCS3 is found in lymphoid tissues as well as non-lymphoid ones. Its best applications are as follows:
SOCS3 blocks signaling via Gc-cytokine receptor. However, SOCS3 inhibits cytokine signaling through the inhibition of JAK activity. This is because SOCS3 interacts with the pTyr-related motifs on the cytokine receptor. SOCS3 cannot, however, hinder signaling through the JAK pathway by itself. It blocks the activity receptor-associated JAKs.
The SOCS3 marker is a widely expressed molecule in a variety of tissues. It is present at high levels in the heart and skeletal muscle peripheral blood leukocytes adult and fetal lung and the thymus. Its amino acid sequence is identical to the mouse's, but differs from the closely similar rat protein by an amino acid. This makes it a possible IHC mediator.
SOCS3 blocks signaling by controlling the activity of cytokines, including GCSF and Leptin. Its inhibitory function depends on its binding to target proteins. SOCS3 reduces the activity of JAK2 kinase, and regulates IL-6 signaling. It could be a substrate recognition component of the E3 ubiquitin-protein ligase complex which is responsible for the degradation of target proteins.
SOCS3 partially regulates OIR's increased production of VEGF. VEGF is an important angiogenic factor, affects vascular endothelial cells. This results in retinal Neovascularization. Hypoxia-inducible protein 1-alpha induces VEGF expression. This stabilizes HIF-1a and transcriptionally activates Vegf.
This study showed that the SOCS3 marker blocked astrocyte reactivity both in vivo and in vitro models. It is possible to identify glioma cells in CRC tissues with IHC methods. The high level of expression in cancer cells suggests it could be a unique method of diagnosis for CRC that is in its early stages. If these findings are confirmed, it could lead to the development of new drug targets.
SOCS3 was also effective in reversing learning deficiencies in APP mice. It improved spatial learning and memory in WTGFP mice, and decreased astrocyte reactivity for APP-GFP mice. In addition, it did NOT affect the speed of swimming. It was also revealed that SOCS3 interfered with JAK2-STAT3 pathways which are essential for inducing and maintaining reactive astrocytes.
The SOCS3 marker can be used as a biomarker to detect various infectious diseases. It has been demonstrated to be essential in the development of immunity to M. tuberculosis and LysM infections. The protein has been shown to regulate the signaling pathway that is mediated by IL-6 and STAT3 and contribute to CD4+ cells that express IFN-g dependently.
Studies have revealed that SOCS3 expression is associated with the replication of HIV in an SIV/macaque model of HIV-associated dementia. SOCS3 inhibits the macrophage response to IFN-b, which allows HIV-1 to bypass the protective immune system that is part of the CNS. Other studies have shown that SOCS3 can affect the outcome of intracellular infections that includes viruses and bacteria.
Souss-Obermann et al. discovered that SOCS1 expression was significantly associated with SOCS3 expression. Additionally, SOCS3 and ELOB showed significant positive correlations. The SOCS3 gene also showed a significant positive correlation with KRAS and HRAS. But, this connection is still being investigated and is not yet definitive. This research is still in its early stages and cannot be used to determine the likelihood of survival from HCC.
The two genes SOCS3 and CXCL8 have overlapping functions, but their effects differ. Both genes are involved with tumor angiogenesis but their expression levels might not be in a relationship. They could be related and a positive correlation is associated with better outcomes. This study will assist in understanding the function played by SOCS3 in tumors.
Socs3 and Cdk2 have negative correlations to each other in the TCGA dataset. The presence of both markers can suggest a poor prognosis of a PH- or DEN-induced HCC. Thus, ICC use of SOCS1 or SOCS3 in cancer research is crucial. Let's now look at how SOCS1 & SOCS3 can be used to predict survival rates based on molecular tests.
BSMCs were grown in Dulbecco's modified Eagle's Medium (DMEM) which contained 10% fetal bovine serum, penicillin, streptomycin, and glutamine. Cells were kept at 37 degrees Celsius in a humidified air environment. The passages two to five were taken out when cells reached 90 percent confluency. The next steps were performed for passages six through seven.
The SOCS3 gene encodes eight structurally similar proteins that are involved in cellular activation, multiplication and replication. It has been found to play a positive regulatory role in fibrosis aswell in cardiac fibrosis. This study demonstrates that SOCS3 expression in BSMCs is high. Silencing SOCS3 expression increases bladder fibrosis in BOO induced BMSCs. Additionally, silencing miR-203 and SOCS3 led to lower levels of fibrotic genes.
Several recent studies have identified the circPVT1 protein and SOCS3 protein in the development of bladder fibrosis. SOCS3 expressions induced by hypoxia were linked to an increase in circPVT1. This suggests that SOCS3 could be used to detect bladder fibrosis or hypertrophy. Furthermore, miR-203 and the SOCS3 exhibit an inverse relationship to circPVT1.
The increasing availability of SOCS3-based glycan detection agents will speed up biological discovery. Antibodies with high affinity and high affinity have been produced in avian and lamprey hosts. Glycan processing enzymes could also be used as binding reagents. Plant or microbial lectins may develop to have high specificity.
This discovery opens the door to new ways to treat the SOCS3 protein. The SOCS3 protein, which is an integrin-like receptor, is expressed on many subtypes of immune cells. It is involved in numerous processes and diseases, including infectious diseases and cancer. Earlier work on the Siglecs focused on the identification of useful cell markers. Research on SOCS3 is at its infancy, but there are many potential uses for this protein.
PMID: 9266833 by Minamoto S., et al. Cloning and functional analysis of new members of STAT induced STAT inhibitor (SSI) family: SSI-2 and SSI-3.
PMID: 9344848 by Masuhara M., et al. Cloning and characterization of novel CIS family genes.
*More publications can be found for each product on its corresponding product page